BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
J Cancer Res Clin Oncol. 2024 Mar 27;150(3):162. doi: 10.1007/s00432-024-05675-9.ABSTRACTBRAF mutations are found in 1-5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been confirmed that targeted therapy with dabrafenib + trametinib is effective in patients with metastatic NSCLC carrying BRAF V600E mutations. Preclinical studies have shown that dabrafenib + trametinib may also have inhibitory effects on some types of non-V600E mutations, especially some class II BRAF mutations. However, the efficacy of dabrafenib + trametinib on non-V600E mutant NSCLC in clinic...
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Lan Jiang Pirong Yang Yufeng Liu Juan Li Source Type: research
Retrospective Study of Lung Cancer: Evolution in 16 Years in the Burgos Region
Conclusions: The findings will not only inform resource management and prevention but could also have a significant impact on improved screening strategies and future lung cancer research.PMID:38541827 | DOI:10.3390/jcm13061601 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Gustavo Guti érrez Herrero Sandra N úñez-Rodríguez Carla Collazo Álvaro García-Bustillo Jer ónimo J González-Bernal Luc ía Castellanos-Romero Josefa Gonz ález-Santos Source Type: research
Texture Features of (18)F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer
Conclusions: Our findings revealed that FDG PET texture features are potential imaging biomarkers for predicting PD-L1 expression in patients newly diagnosed with NSCLC.PMID:38541851 | DOI:10.3390/jcm13061625 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Takashi Norikane Mariko Ishimura Katsuya Mitamura Yuka Yamamoto Hanae Arai-Okuda Yuri Manabe Mitsumasa Murao Riku Morita Takafumi Obata Kenichi Tanaka Makiko Murota Nobuhiro Kanaji Yoshihiro Nishiyama Source Type: research
Robotic Lobectomy Learning Curve Has Better Clinical Outcomes than Videothoracoscopic Lobectomy
Conclusions: The RATS curve appears shorter than the VATS curve. RATS lobectomies resulted in reduced chest tube duration and length of stay during the learning time period.PMID:38541879 | DOI:10.3390/jcm13061653 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Pablo Luis Paglialunga Laureano Molins Rudith Guzm án Angela Guirao Irene Bello Anna Ure ña Leandro Grando Nestor Quiroga Xavier Michavila Marc Boada Source Type: research
Diagnostic Accuracy in Detecting Fungal Infection with Ultra-Low-Dose Computed Tomography (ULD-CT) Using Filtered Back Projection (FBP) Technique in Immunocompromised Patients
Conclusions: Thoracic uLDCT, at a 75% dose reduction, can replace LDCT for the detection of fungal disease in IC patients with BMI < 30.0 kg/m2.PMID:38541929 | DOI:10.3390/jcm13061704 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Luigia D'Errico Anita Ghali Mini Pakkal Micheal McInnis Hatem Mehrez Andre C Schuh John G Kuruvilla Mark Minden Narinder S Paul Source Type: research
Visual scoring of osteoporosis on low-dose CT in lung cancer screening population
CONCLUSIONS: Our study shows that a simple approach of applying specific window width and level settings to already reconstructed sagittal images obtained in the context of low-dose CT screening for lung cancer is highly feasible and useful in identifying osteoporosis.PMID:38547669 | DOI:10.1016/j.clinimag.2024.110115 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Yeqing Zhu Rowena Yip Artit C Jirapatnakul Mingqian Huang Qiang Cai Etan Dayan Li Liu Anthony P Reeves Claudia I Henschke David F Yankelevitz Source Type: research
Exploring the Oncogenic Potential of TIMM8A: A Crucial Factor in Breast Cancer Tumorigenesis
CONCLUSION: This study revealed that TIMM8A is an oncogene and is critical for the tumorigenesis of breast carcinoma.PMID:38548519 | DOI:10.1016/j.clbc.2024.02.011 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 28, 2024 Category: Cancer & Oncology Authors: Yili Chi Suzita Hirachan Yuying Zhou Adheesh Bhandari Source Type: research
Correction: A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle
J Exp Clin Cancer Res. 2024 Mar 26;43(1):93. doi: 10.1186/s13046-024-03018-7.NO ABSTRACTPMID:38532446 | PMC:PMC10964550 | DOI:10.1186/s13046-024-03018-7 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Bolin Wang Jinli Pei Shengnan Xu Jie Liu Jinming Yu Source Type: research
Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups
CONCLUSION: the number of multicentre clinical trials in oncology gradually decreased after the Clinical Trials Act's enforcement, which underscores the need for comprehensive amendment of the Clinical Trials Act to streamline the operational process.PMID:38535873 | DOI:10.1093/jjco/hyae034 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Kenichi Nakamura Koji Takeda Akiko M Saito Miho Kato Shinya Sato Satoshi Nakagawa Yasuyuki Kawamoto Eiji Oki Isamu Okamoto Hiroaki Okamoto Hiroshi Katayama Junki Mizusawa Harumi Kaba Taro Shibata Haruhiko Fukuda Source Type: research
Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
CONCLUSIONS: Locally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery > 8 weeks were associated with worse long-term survival.PMID:38536527 | DOI:10.1007/s00432-024-05696-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Jiacong Liu Linhai Zhu Xuhua Huang Zhongjie Lu Yanye Wang Yuhong Yang Jiayue Ye Chen Gu Wang Lv Chong Zhang Jian Hu Source Type: research
Toward Racial Equity in Lung Cancer Screening Eligibility
J Clin Oncol. 2024 Mar 27:JCO2400351. doi: 10.1200/JCO.24.00351. Online ahead of print.NO ABSTRACTPMID:38537157 | DOI:10.1200/JCO.24.00351 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hasmeena Kathuria Renda Soylemez Wiener Source Type: research
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022
CONCLUSION: The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.PMID:38537158 | DOI:10.1200/JCO.23.01777 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hong Xiao Riha Vaidya Dawn L Hershman Joseph M Unger Source Type: research
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility
CONCLUSION: Use of a 20-year smoking duration cutoff instead of a 20-pack-year cutoff greatly increases the proportion of patients with lung cancer who would qualify for screening and eliminates the racial disparity in screening eligibility between Black versus White individuals; smoking duration has the added benefit of being easier to calculate and being a more precise assessment of smoking exposure compared with pack-year smoking history.PMID:38537159 | DOI:10.1200/JCO.23.01780 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Alexandra L Potter Nuo N Xu Priyanka Senthil Deepti Srinivasan Hang Lee G Scott Gazelle Lydia Chelala Wei Zheng Florian J Fintelmann Lecia V Sequist Jessica Donington Julie R Palmer Chi-Fu Jeffrey Yang Source Type: research
Correction: A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle
J Exp Clin Cancer Res. 2024 Mar 26;43(1):93. doi: 10.1186/s13046-024-03018-7.NO ABSTRACTPMID:38532446 | DOI:10.1186/s13046-024-03018-7 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Bolin Wang Jinli Pei Shengnan Xu Jie Liu Jinming Yu Source Type: research
Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups
CONCLUSION: the number of multicentre clinical trials in oncology gradually decreased after the Clinical Trials Act's enforcement, which underscores the need for comprehensive amendment of the Clinical Trials Act to streamline the operational process.PMID:38535873 | DOI:10.1093/jjco/hyae034 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Kenichi Nakamura Koji Takeda Akiko M Saito Miho Kato Shinya Sato Satoshi Nakagawa Yasuyuki Kawamoto Eiji Oki Isamu Okamoto Hiroaki Okamoto Hiroshi Katayama Junki Mizusawa Harumi Kaba Taro Shibata Haruhiko Fukuda Source Type: research
